Evidence map›Paper›PMID 36989943›Full record

ReviewCurrent opinion in chemical biology2023

Platinum-based combination nanomedicines for cancer therapy.

Youyou Li, Wenbin Lin

Open access · greenAbstract readReview
In one paragraph

Review in Current opinion in chemical biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Youyou LiDepartment of Chemistry, The University of Chicago, 929 E 57th St, Chicago, IL 60637, USA.
Wenbin LinDepartment of Chemistry, The University of Chicago, 929 E 57th St, Chicago, IL 60637, USA; Department of Radiation and Cellular Oncology and Ludwig Center for Metastasis Research, The University of Chicago, 5758, S Maryland Ave, Chicago, IL 60637, USA. Electronic address: wenbinlin@uchicago.edu.
University of Chicago · US

Funding

Nanoscale Coordination Polymers Co-deliver Chemotherapeutics and siRNAs for Efficacious Treatment of Resistant Ovarian CancerR01CA216436 · NCI · UNIVERSITY OF CHICAGO · PI LIN, WENBIN · 2018 to 2022
$2.1M
Targeted Nanomedicines with Synergistic Chemotherapeutics to Enhance Immunotherapy of Metastatic Colorectal CancerR01CA223184 · NCI · UNIVERSITY OF CHICAGO · PI LIN, WENBIN · 2018 to 2022
$1.8M
NCI NIH HHS R01 CA216436NCI NIH HHS R01 CA223184
6 · The paper itself

Abstract

The relatively low success rate of cancer nanomedicines has raised debate on the roles of the enhanced permeability and retention (EPR) effect in enhancing drug delivery to tumors and improving therapeutic efficacy. In this review, we highlight new strategies beyond the EPR effect for enhancing nanoparticle delivery to tumors. We discuss the roles of transcellular extravasation, receptor-mediated pathways, and protein corona interactions on nanoparticle deposition in tumors. We summarize recent progress in platinum-based combination nanomedicines containing multiple chemotherapeutics with synergistic anticancer mechanisms and multiple anticancer therapies with novel mechanisms to enhance drug delivery and antitumor activities. We also highlight future opportunities in platinum-based combination nanomedicines and key hurdles for the translation of these combination nanomedicines into the clinic.

Indexed as

Antineoplastic AgentsNanoparticlesNeoplasmsDrug Delivery SystemsHumansNanomedicineAntineoplastic AgentsCombination cancer therapyNanomedicinePlatinum-based drugs

Identifiers

PMID36989943
PMCPMC10225318
OpenAlexW4361225572

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.